home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »


Feb4Nevro Receives Expanded MR-Conditional Labeling for Senza® Spinal Cord Stimulation System in Europe and Australia

Senza is the first implantable spinal cord stimulator system that is 3 Tesla MRI compatible 


Menlo Park, Calif., Feb. 4, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that it has received CE Mark for expanded MR-conditional labeling. The labeling expansion now permits the Senza spinal cord stimulation (SCS) system to be marketed in Europe and Australia for scans of the head and extremities with both 1.5 and 3 Tesla (T) MRI machines under specified conditions for existing and future patients.


"Spinal cord stimulation is an important tool in treating chronic pain, and the addition of 3T compatibility and extremities labeling is a significant advancement that provides HF10 therapy patients access to additional diagnostic tools," said Dr. Paul Verrills, President of the Australian & New Zealand Neuromodulation Society.


With the new MR-conditional labeling, Nevro is now the first company to offer MRI compatibility with 3T machines for an implantable SCS system. The new labeling includes all generations of the Senza SCS system dating back to 2010 and applies to all geographies where Nevro currently sells the system commercially.


"We are pleased to offer even more imaging options for our patients. Nevro is a company that is continually looking to advance the SCS space, and this expanded MR-conditional labeling highlights our ongoing commitment to innovation," said Michael DeMane, Chairman and Chief Executive Officer of Nevro.




The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy, an SCS therapy that provides electrical pulses to the spinal cord to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin. As demonstrated in the SENZA-RCT study, HF10 therapy provides pain relief without paresthesia (a constant tingling sensation that is the basis of traditional SCS therapy).




Headquartered in Menlo Park, California, Nevro is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. In the United States, the Senza system is limited by federal law to investigational use only.  Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.


To view the original version on PR Newswire, visit:prnewswire.com


SOURCE Nevro Corp.


Investor Relations Contact: Westwicke Partners, Lynn Pieper, (415) 202-5678, Lynn.pieper@westwicke.com